Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer

Yasuhide Miyoshi, Hitoshi Ishiguro, Hiroji Uemura, Kiyoshi Fujinami, Hiroshi Miyamoto, Yoshiko Miyoshi, Hitoshi Kitamura, Yoshinobu Kubota

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Androgen receptor (AR) transcription is modulated by several cofactors such as AR associated proteins (ARA) including ARA70, ARA54, and ARA55. ARA55 increases AR transcription and alters ligand specificity. We hypothesized that ARA55 might play an important role in prostate cancer development or progression. We evaluated the messenger RNA (mRNA) expression of ARA55 in prostate cancer tissues, and analyzed the relation between ARA55 expression and clinical characteristics. METHODS. A total of 30 prostate cancer specimens (20 previously untreated prostate cancers and 10 recurrent, hormone-refractory prostate cancers (HRPC)) and 5 benign prostatic hypertrophy (BPH) tissue samples were examined. mRNA expression of ARA55 and AR were analyzed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using real time PCR. RESULTS. ARA55 expression was identified in all tissue samples of previously untreated prostate cancer, HRPC and BPH. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer (P = 0.02) or BPH (P = 0.005) samples using quantitative PCR. On the other hand, higher ARA55 expression was associated with shorter recurrence-free survival (P = 0.02) and overall survival (P = 0.01) in HRPC patients. AR expression was also revealed in all specimens of both prostate cancer and BPH. AR expression level in HRPC samples was significantly higher than that in previously untreated prostate cancer (P = 0.001) and BPH (P = 0.01) samples. CONCLUSIONS. ARA55 may be associated with prostate cancer development and progression. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer or BPH specimens. On the contrary, our results suggested that a higher ARA55 expression level may result in unfavorable recurrence-free survival and overall survival in HRPC patients. The role of ARA55 may differ between prostate cancer development and the process of progression to a hormone-refractory state. These data not only help to understand the molecular mechanism of prostate cancer development or recurrence, but may also lead to a therapeutic strategy for recurrent prostate cancer that is refractory to hormonal treatment.

Original languageEnglish (US)
Pages (from-to)280-286
Number of pages7
JournalProstate
Volume56
Issue number4
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Proteins
Prostatic Hyperplasia
Hormones
Survival
Recurrence
Messenger RNA

Keywords

  • Androgen receptor (AR)
  • ARA55
  • Cofactor
  • Coregulator
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Miyoshi, Y., Ishiguro, H., Uemura, H., Fujinami, K., Miyamoto, H., Miyoshi, Y., ... Kubota, Y. (2003). Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate, 56(4), 280-286. https://doi.org/10.1002/pros.10262

Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. / Miyoshi, Yasuhide; Ishiguro, Hitoshi; Uemura, Hiroji; Fujinami, Kiyoshi; Miyamoto, Hiroshi; Miyoshi, Yoshiko; Kitamura, Hitoshi; Kubota, Yoshinobu.

In: Prostate, Vol. 56, No. 4, 01.09.2003, p. 280-286.

Research output: Contribution to journalArticle

Miyoshi, Y, Ishiguro, H, Uemura, H, Fujinami, K, Miyamoto, H, Miyoshi, Y, Kitamura, H & Kubota, Y 2003, 'Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer', Prostate, vol. 56, no. 4, pp. 280-286. https://doi.org/10.1002/pros.10262
Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate. 2003 Sep 1;56(4):280-286. https://doi.org/10.1002/pros.10262
Miyoshi, Yasuhide ; Ishiguro, Hitoshi ; Uemura, Hiroji ; Fujinami, Kiyoshi ; Miyamoto, Hiroshi ; Miyoshi, Yoshiko ; Kitamura, Hitoshi ; Kubota, Yoshinobu. / Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. In: Prostate. 2003 ; Vol. 56, No. 4. pp. 280-286.
@article{454b942c2bba43a9aaaed337a2faf96d,
title = "Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer",
abstract = "BACKGROUND. Androgen receptor (AR) transcription is modulated by several cofactors such as AR associated proteins (ARA) including ARA70, ARA54, and ARA55. ARA55 increases AR transcription and alters ligand specificity. We hypothesized that ARA55 might play an important role in prostate cancer development or progression. We evaluated the messenger RNA (mRNA) expression of ARA55 in prostate cancer tissues, and analyzed the relation between ARA55 expression and clinical characteristics. METHODS. A total of 30 prostate cancer specimens (20 previously untreated prostate cancers and 10 recurrent, hormone-refractory prostate cancers (HRPC)) and 5 benign prostatic hypertrophy (BPH) tissue samples were examined. mRNA expression of ARA55 and AR were analyzed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using real time PCR. RESULTS. ARA55 expression was identified in all tissue samples of previously untreated prostate cancer, HRPC and BPH. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer (P = 0.02) or BPH (P = 0.005) samples using quantitative PCR. On the other hand, higher ARA55 expression was associated with shorter recurrence-free survival (P = 0.02) and overall survival (P = 0.01) in HRPC patients. AR expression was also revealed in all specimens of both prostate cancer and BPH. AR expression level in HRPC samples was significantly higher than that in previously untreated prostate cancer (P = 0.001) and BPH (P = 0.01) samples. CONCLUSIONS. ARA55 may be associated with prostate cancer development and progression. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer or BPH specimens. On the contrary, our results suggested that a higher ARA55 expression level may result in unfavorable recurrence-free survival and overall survival in HRPC patients. The role of ARA55 may differ between prostate cancer development and the process of progression to a hormone-refractory state. These data not only help to understand the molecular mechanism of prostate cancer development or recurrence, but may also lead to a therapeutic strategy for recurrent prostate cancer that is refractory to hormonal treatment.",
keywords = "Androgen receptor (AR), ARA55, Cofactor, Coregulator, Prostate cancer",
author = "Yasuhide Miyoshi and Hitoshi Ishiguro and Hiroji Uemura and Kiyoshi Fujinami and Hiroshi Miyamoto and Yoshiko Miyoshi and Hitoshi Kitamura and Yoshinobu Kubota",
year = "2003",
month = "9",
day = "1",
doi = "10.1002/pros.10262",
language = "English (US)",
volume = "56",
pages = "280--286",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer

AU - Miyoshi, Yasuhide

AU - Ishiguro, Hitoshi

AU - Uemura, Hiroji

AU - Fujinami, Kiyoshi

AU - Miyamoto, Hiroshi

AU - Miyoshi, Yoshiko

AU - Kitamura, Hitoshi

AU - Kubota, Yoshinobu

PY - 2003/9/1

Y1 - 2003/9/1

N2 - BACKGROUND. Androgen receptor (AR) transcription is modulated by several cofactors such as AR associated proteins (ARA) including ARA70, ARA54, and ARA55. ARA55 increases AR transcription and alters ligand specificity. We hypothesized that ARA55 might play an important role in prostate cancer development or progression. We evaluated the messenger RNA (mRNA) expression of ARA55 in prostate cancer tissues, and analyzed the relation between ARA55 expression and clinical characteristics. METHODS. A total of 30 prostate cancer specimens (20 previously untreated prostate cancers and 10 recurrent, hormone-refractory prostate cancers (HRPC)) and 5 benign prostatic hypertrophy (BPH) tissue samples were examined. mRNA expression of ARA55 and AR were analyzed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using real time PCR. RESULTS. ARA55 expression was identified in all tissue samples of previously untreated prostate cancer, HRPC and BPH. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer (P = 0.02) or BPH (P = 0.005) samples using quantitative PCR. On the other hand, higher ARA55 expression was associated with shorter recurrence-free survival (P = 0.02) and overall survival (P = 0.01) in HRPC patients. AR expression was also revealed in all specimens of both prostate cancer and BPH. AR expression level in HRPC samples was significantly higher than that in previously untreated prostate cancer (P = 0.001) and BPH (P = 0.01) samples. CONCLUSIONS. ARA55 may be associated with prostate cancer development and progression. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer or BPH specimens. On the contrary, our results suggested that a higher ARA55 expression level may result in unfavorable recurrence-free survival and overall survival in HRPC patients. The role of ARA55 may differ between prostate cancer development and the process of progression to a hormone-refractory state. These data not only help to understand the molecular mechanism of prostate cancer development or recurrence, but may also lead to a therapeutic strategy for recurrent prostate cancer that is refractory to hormonal treatment.

AB - BACKGROUND. Androgen receptor (AR) transcription is modulated by several cofactors such as AR associated proteins (ARA) including ARA70, ARA54, and ARA55. ARA55 increases AR transcription and alters ligand specificity. We hypothesized that ARA55 might play an important role in prostate cancer development or progression. We evaluated the messenger RNA (mRNA) expression of ARA55 in prostate cancer tissues, and analyzed the relation between ARA55 expression and clinical characteristics. METHODS. A total of 30 prostate cancer specimens (20 previously untreated prostate cancers and 10 recurrent, hormone-refractory prostate cancers (HRPC)) and 5 benign prostatic hypertrophy (BPH) tissue samples were examined. mRNA expression of ARA55 and AR were analyzed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using real time PCR. RESULTS. ARA55 expression was identified in all tissue samples of previously untreated prostate cancer, HRPC and BPH. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer (P = 0.02) or BPH (P = 0.005) samples using quantitative PCR. On the other hand, higher ARA55 expression was associated with shorter recurrence-free survival (P = 0.02) and overall survival (P = 0.01) in HRPC patients. AR expression was also revealed in all specimens of both prostate cancer and BPH. AR expression level in HRPC samples was significantly higher than that in previously untreated prostate cancer (P = 0.001) and BPH (P = 0.01) samples. CONCLUSIONS. ARA55 may be associated with prostate cancer development and progression. ARA55 expression level in HRPC specimens was significantly lower than that in previously untreated prostate cancer or BPH specimens. On the contrary, our results suggested that a higher ARA55 expression level may result in unfavorable recurrence-free survival and overall survival in HRPC patients. The role of ARA55 may differ between prostate cancer development and the process of progression to a hormone-refractory state. These data not only help to understand the molecular mechanism of prostate cancer development or recurrence, but may also lead to a therapeutic strategy for recurrent prostate cancer that is refractory to hormonal treatment.

KW - Androgen receptor (AR)

KW - ARA55

KW - Cofactor

KW - Coregulator

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0041730569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041730569&partnerID=8YFLogxK

U2 - 10.1002/pros.10262

DO - 10.1002/pros.10262

M3 - Article

C2 - 12858356

AN - SCOPUS:0041730569

VL - 56

SP - 280

EP - 286

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -